Coventry breast cancer patients among those to test innovative drug

By Matthew Bates Thursday 13 December 2012 Updated: 14/12 16:09

PATIENTS at University Hospital were among those to trial a new breast cancer drug.

Data from trials for drug Perjeta indicated it reduces the risk of death by up to a third in patients with previously untreated breast cancer when compared with current standards.

The study, by the San Antonio Breast Cancer Symposium, showed a 'clear and improving' benefit for HER2-positive patients over fellow drug Herceptin and chemotherapy alone.

Over 800 cancer sufferers took part in the trial overall. University Hospital did not release figures of how many patients had taken part.

Professor Chris Poole, Professor of Medical Oncology at the Walsgrave site, said the results were impressive.

"To find a treatment that can control HER2-positive breast cancer for longer and extend patients’ lives compared with the current gold-standard is rare – especially when it does not compromise quality of life.

"Perjeta has been shown to boost the effects of Herceptin, which revolutionised the treatment of HER2-positive breast cancer over a decade ago.

"This development marks an exciting step forward and will positively alter the outlook and outcomes for patients with this aggressive form of cancer in the future."

Regional news »


Rugby Observer
HS2 cash for communities 'derisory'

COUNCIL chiefs have branded cash for communities affected by HS2 ...

Solihull Observer
Mum's support wins a surprise Beacon award

A ‘WONDERFUL and amazing’ mother has been handed a top ...

Leamington Observer
HS2 cash for communities 'derisory'

COUNCIL chiefs have branded cash for communities affected by HS2 ...

Redditch Standard
Victims to choose criminals' punishment

VICTIMS of crime in Redditch, Studley and Alcester are now ...